Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Zantac

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging that Zantac, or its generic ranitidine, can cause cancer.

Benzinga

Despite Profit Fallout, GSK Remains Optimist For 2031 Revenue Target Amidst Cancer Drug Sale Rise

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

International Business Times UK

FTSE 100 Live 30 October: Next forecasts £1bn profit, GSK vaccine sales weakness hits shares

A £1 billion profits landmark for Next and strong trading at Standard Chartered today provided FTSE 100 cheer during another painful session for GSK investors.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac

British drugmaker agrees payment to resolve 80,000 cases alleging cancers were linked to drug known generically as ranitidine

The Guardian - UK

FTSE 100 Live 3 June: New York trading glitch sparks volatility, GSK shares tumble

BP and Shell shares today hindered FTSE 100 progress after oil prices fell to their lowest level since February.

Evening Standard

Sanofi To Settle Around 4,000 Suits Over Zantac Cancer Allegations

Sanofi will settle around 4,000 claims alleging its heartburn medication, Zantac, is linked to cancer.

International Business Times

GSK Settles California Lawsuit On Zantac Heartburn Drug

GSK reaches settlement in California lawsuit related to Zantac amidst ongoing legal challenges over cancer risks.

Top News

Read news from The Economist, FT, and more,
with one subscription

1 Pharma Stock to Buy Near 52-Week Highs

GSK's stock has been a poor performer for years. But recently, the pharma stock keeps setting new 52-week highs, thanks to its blockbuster vaccines.

Barchart

Moonpig flotation price, like so many, was always pie-in-the-sky thinking

You’d think fund mangers would have deployed degree of scepticism after years of overvalued businesses

The Guardian - UK

GSK shares surge as US judge dismisses Zantac cancer claims

About 50,000 federal lawsuits claimed that the best-selling heartburn drug had led to cancer

The Guardian - UK

The only party not getting heartburn over GSK demerger is the lawyers

The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years

The Guardian - UK

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.